vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Mueller Water Products, Inc. (MWA). Click either name above to swap in a different company.
Mueller Water Products, Inc. is the larger business by last-quarter revenue ($318.2M vs $183.1M, roughly 1.7× Amphastar Pharmaceuticals, Inc.). Mueller Water Products, Inc. runs the higher net margin — 13.6% vs 13.3%, a 0.2% gap on every dollar of revenue. On growth, Mueller Water Products, Inc. posted the faster year-over-year revenue change (4.6% vs -1.8%). Mueller Water Products, Inc. produced more free cash flow last quarter ($44.0M vs $24.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -5.1%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Mueller Water Products, Inc. (MWP) is a publicly traded company headquartered in Atlanta, Georgia. It is one of the largest manufacturers and distributors of fire hydrants, gate valves, and other water infrastructure products in North America. MWP is made up of two business units—Mueller Co. and Mueller Technologies—that oversee more than a dozen brands and affiliates, including Echologics and Mueller Systems.
AMPH vs MWA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $318.2M |
| Net Profit | $24.4M | $43.2M |
| Gross Margin | 46.8% | 37.6% |
| Operating Margin | 19.4% | 17.8% |
| Net Margin | 13.3% | 13.6% |
| Revenue YoY | -1.8% | 4.6% |
| Net Profit YoY | -35.7% | 22.4% |
| EPS (diluted) | $0.51 | $0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $318.2M | ||
| Q3 25 | $191.8M | $380.8M | ||
| Q2 25 | $174.4M | $380.3M | ||
| Q1 25 | $170.5M | $364.3M | ||
| Q4 24 | $186.5M | $304.3M | ||
| Q3 24 | $191.2M | $348.2M | ||
| Q2 24 | $182.4M | $356.7M | ||
| Q1 24 | $171.8M | $353.4M |
| Q4 25 | $24.4M | $43.2M | ||
| Q3 25 | $17.4M | $52.6M | ||
| Q2 25 | $31.0M | $52.5M | ||
| Q1 25 | $25.3M | $51.3M | ||
| Q4 24 | $38.0M | $35.3M | ||
| Q3 24 | $40.4M | $10.0M | ||
| Q2 24 | $37.9M | $47.3M | ||
| Q1 24 | $43.2M | $44.3M |
| Q4 25 | 46.8% | 37.6% | ||
| Q3 25 | 51.4% | 36.8% | ||
| Q2 25 | 49.6% | 38.3% | ||
| Q1 25 | 50.0% | 35.1% | ||
| Q4 24 | 46.5% | 33.8% | ||
| Q3 24 | 53.3% | 31.8% | ||
| Q2 24 | 52.2% | 36.8% | ||
| Q1 24 | 52.4% | 36.9% |
| Q4 25 | 19.4% | 17.8% | ||
| Q3 25 | 13.2% | 18.3% | ||
| Q2 25 | 24.2% | 19.4% | ||
| Q1 25 | 21.9% | 19.2% | ||
| Q4 24 | 24.2% | 15.6% | ||
| Q3 24 | 29.8% | 8.2% | ||
| Q2 24 | 30.3% | 18.8% | ||
| Q1 24 | 27.9% | 18.0% |
| Q4 25 | 13.3% | 13.6% | ||
| Q3 25 | 9.0% | 13.8% | ||
| Q2 25 | 17.8% | 13.8% | ||
| Q1 25 | 14.8% | 14.1% | ||
| Q4 24 | 20.4% | 11.6% | ||
| Q3 24 | 21.1% | 2.9% | ||
| Q2 24 | 20.8% | 13.3% | ||
| Q1 24 | 25.1% | 12.5% |
| Q4 25 | $0.51 | $0.27 | ||
| Q3 25 | $0.37 | $0.34 | ||
| Q2 25 | $0.64 | $0.33 | ||
| Q1 25 | $0.51 | $0.33 | ||
| Q4 24 | $0.74 | $0.22 | ||
| Q3 24 | $0.78 | $0.07 | ||
| Q2 24 | $0.73 | $0.30 | ||
| Q1 24 | $0.81 | $0.28 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | — |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $1.0B |
| Total Assets | $1.6B | $1.8B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — | ||
| Q1 24 | $289.6M | — |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $1.0B | ||
| Q3 25 | $776.7M | $981.7M | ||
| Q2 25 | $757.5M | $929.0M | ||
| Q1 25 | $751.3M | $873.6M | ||
| Q4 24 | $732.3M | $834.1M | ||
| Q3 24 | $727.7M | $810.1M | ||
| Q2 24 | $713.3M | $791.6M | ||
| Q1 24 | $672.4M | $754.5M |
| Q4 25 | $1.6B | $1.8B | ||
| Q3 25 | $1.7B | $1.8B | ||
| Q2 25 | $1.6B | $1.7B | ||
| Q1 25 | $1.6B | $1.7B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.6B | $1.5B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $61.2M |
| Free Cash FlowOCF − Capex | $24.6M | $44.0M |
| FCF MarginFCF / Revenue | 13.4% | 13.8% |
| Capex IntensityCapex / Revenue | 4.5% | 5.4% |
| Cash ConversionOCF / Net Profit | 1.35× | 1.42× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $173.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $61.2M | ||
| Q3 25 | $52.6M | $83.5M | ||
| Q2 25 | $35.6M | $67.4M | ||
| Q1 25 | $35.1M | $14.3M | ||
| Q4 24 | $29.0M | $54.1M | ||
| Q3 24 | $60.0M | $89.3M | ||
| Q2 24 | $69.1M | $87.3M | ||
| Q1 24 | $55.3M | $-5.7M |
| Q4 25 | $24.6M | $44.0M | ||
| Q3 25 | $47.2M | $69.0M | ||
| Q2 25 | $25.0M | $55.7M | ||
| Q1 25 | $24.4M | $5.1M | ||
| Q4 24 | $16.6M | $42.2M | ||
| Q3 24 | $46.2M | $69.9M | ||
| Q2 24 | $63.1M | $75.1M | ||
| Q1 24 | $46.5M | $-15.8M |
| Q4 25 | 13.4% | 13.8% | ||
| Q3 25 | 24.6% | 18.1% | ||
| Q2 25 | 14.3% | 14.6% | ||
| Q1 25 | 14.3% | 1.4% | ||
| Q4 24 | 8.9% | 13.9% | ||
| Q3 24 | 24.1% | 20.1% | ||
| Q2 24 | 34.6% | 21.1% | ||
| Q1 24 | 27.1% | -4.5% |
| Q4 25 | 4.5% | 5.4% | ||
| Q3 25 | 2.8% | 3.8% | ||
| Q2 25 | 6.1% | 3.1% | ||
| Q1 25 | 6.3% | 2.5% | ||
| Q4 24 | 6.7% | 3.9% | ||
| Q3 24 | 7.2% | 5.6% | ||
| Q2 24 | 3.3% | 3.4% | ||
| Q1 24 | 5.1% | 2.9% |
| Q4 25 | 1.35× | 1.42× | ||
| Q3 25 | 3.03× | 1.59× | ||
| Q2 25 | 1.15× | 1.28× | ||
| Q1 25 | 1.39× | 0.28× | ||
| Q4 24 | 0.76× | 1.53× | ||
| Q3 24 | 1.48× | 8.93× | ||
| Q2 24 | 1.82× | 1.85× | ||
| Q1 24 | 1.28× | -0.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
MWA
| Water Flow Solutions | $173.0M | 54% |
| Water Management Solutions | $145.2M | 46% |
